To learn more, please call our Research Department at (513) 751-2273 or email
mhoelle@ohcare.com
| Metastatic, first-line |
| Study number: |
GU 68 OncoGenex Technologies OGX-011-11 |
| Protocol title: |
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer |
| Status |
Open
|